Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Inverse agonists of the 5-HT2A receptor reduce nicotine withdrawal signs in rats.

Malin D, Henceroth M, Rao GS, Campbell J, Ma JN, Tsai PH, Kishbaugh JC, Burstein ES.

Neurosci Lett. 2019 Nov 20;713:134524. doi: 10.1016/j.neulet.2019.134524. Epub 2019 Oct 1.

PMID:
31585211
2.

Should inverse agonists be defined by pharmacological mechanism or clinical effect?

Burstein ES.

CNS Spectr. 2019 Aug;24(4):349-351. doi: 10.1017/S1092852918001761. Epub 2019 Mar 20. No abstract available.

PMID:
30890194
3.

A subtype-specific neuropeptide FF receptor antagonist attenuates morphine and nicotine withdrawal syndrome in the rat.

Malin DH, Henceroth MM, Elayoubi J, Campbell JR, Anderson A, Goyarzu P, Izygon J, Madison CA, Ward CP, Burstein ES.

Neurosci Lett. 2018 Sep 25;684:98-103. doi: 10.1016/j.neulet.2018.06.053. Epub 2018 Jul 5.

PMID:
29981879
4.

Ligand Dependent Switch from RXR Homo- to RXR-NURR1 Heterodimerization.

Scheepstra M, Andrei SA, de Vries RMJM, Meijer FA, Ma JN, Burstein ES, Olsson R, Ottmann C, Milroy LG, Brunsveld L.

ACS Chem Neurosci. 2017 Sep 20;8(9):2065-2077. doi: 10.1021/acschemneuro.7b00216. Epub 2017 Jul 24.

5.

Decompression Retinopathy After Goniotomy in a Child: A Case Report.

Burstein ES, Netland PA.

J Glaucoma. 2017 Aug;26(8):747-748. doi: 10.1097/IJG.0000000000000681.

PMID:
28410254
6.

Dronedarone Modulates M1 and M3 Muscarinic Receptors with Subtype Selectivity, Functional Selectivity, and Probe Dependence.

Jayasuriya GM, Elmslie G, Burstein ES, Ellis J.

Pharmacology. 2017;99(3-4):128-138. doi: 10.1159/000453362. Epub 2016 Dec 20.

PMID:
27992867
7.

Preclinical PET Neuroimaging of [11C]Bexarotene.

Rotstein BH, Placzek MS, Krishnan HS, Pekošak A, Collier TL, Wang C, Liang SH, Burstein ES, Hooker JM, Vasdev N.

Mol Imaging. 2016 Aug 23;15. pii: 1536012116663054. doi: 10.1177/1536012116663054. Print 2016.

8.

Estrogen Receptor Beta Selective Agonists as Agents to Treat Chemotherapeutic-Induced Neuropathic Pain.

Ma JN, McFarland K, Olsson R, Burstein ES.

ACS Chem Neurosci. 2016 Sep 21;7(9):1180-7. doi: 10.1021/acschemneuro.6b00183. Epub 2016 Jul 26.

PMID:
27456785
9.

Chiral Dihydrobenzofuran Acids Show Potent Retinoid X Receptor-Nuclear Receptor Related 1 Protein Dimer Activation.

Sundén H, Schäfer A, Scheepstra M, Leysen S, Malo M, Ma JN, Burstein ES, Ottmann C, Brunsveld L, Olsson R.

J Med Chem. 2016 Feb 11;59(3):1232-8. doi: 10.1021/acs.jmedchem.5b01702. Epub 2016 Jan 28.

PMID:
26820900
10.

Reversal of morphine tolerance by a compound with NPFF receptor subtype-selective actions.

Malin DH, Henceroth MM, Izygon JJ, Nghiem DM, Moon WD, Anderson AP, Madison CA, Goyarzu P, Ma JN, Burstein ES.

Neurosci Lett. 2015 Jan 1;584:141-5. doi: 10.1016/j.neulet.2014.10.018. Epub 2014 Oct 20.

11.

On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.

Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H.

Neurochem Res. 2014 Oct;39(10):2008-17. doi: 10.1007/s11064-014-1293-3. Epub 2014 Mar 30. Review.

12.

Bexarotene prodrugs: targeting through cleavage by NQO1 (DT-diaphorase).

Schäfer A, Burstein ES, Olsson R.

Bioorg Med Chem Lett. 2014 Apr 15;24(8):1944-7. doi: 10.1016/j.bmcl.2014.03.003. Epub 2014 Mar 13.

PMID:
24666648
13.

Identification of the antiarrhythmic drugs amiodarone and lorcainide as potent H3 histamine receptor inverse agonists.

Del Tredici AL, Ma JN, Piu F, Burstein ES.

J Pharmacol Exp Ther. 2014 Jan;348(1):116-24. doi: 10.1124/jpet.113.208892. Epub 2013 Nov 7.

PMID:
24204014
14.

Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease.

McFarland K, Spalding TA, Hubbard D, Ma JN, Olsson R, Burstein ES.

ACS Chem Neurosci. 2013 Nov 20;4(11):1430-8. doi: 10.1021/cn400100f. Epub 2013 Oct 11.

15.

The protease activated receptor 2 (PAR2) polymorphic variant F240S constitutively activates PAR2 receptors and potentiates responses to small-molecule PAR2 agonists.

Ma JN, Burstein ES.

J Pharmacol Exp Ther. 2013 Dec;347(3):697-704. doi: 10.1124/jpet.113.208744. Epub 2013 Sep 27.

PMID:
24078870
16.

AC-186, a selective nonsteroidal estrogen receptor β agonist, shows gender specific neuroprotection in a Parkinson's disease rat model.

McFarland K, Price DL, Davis CN, Ma JN, Bonhaus DW, Burstein ES, Olsson R.

ACS Chem Neurosci. 2013 Sep 18;4(9):1249-55. doi: 10.1021/cn400132u. Epub 2013 Aug 6.

17.

Design of a highly selective and potent class of non-planar estrogen receptor β agonists.

Sundén H, Ma JN, Hansen LK, Gustavsson AL, Burstein ES, Olsson R.

ChemMedChem. 2013 Aug;8(8):1283-94. doi: 10.1002/cmdc.201300175. Epub 2013 Jun 19.

PMID:
23784708
18.

Functional enhancement of AT1R potency in the presence of the TPαR is revealed by a comprehensive 7TM receptor co-expression screen.

Hansen JT, Lyngsø C, Speerschneider T, Hansen PB, Galés C, Weiner DM, Sheikh SP, Burstein ES, Hansen JL.

PLoS One. 2013;8(3):e58890. doi: 10.1371/journal.pone.0058890. Epub 2013 Mar 14.

19.

Traumatic ruptured globe eye injuries in a large urban center.

Burstein ES, Lazzaro DR.

Clin Ophthalmol. 2013;7:485-8. doi: 10.2147/OPTH.S42050. Epub 2013 Mar 6.

20.

Discovery of potential antipsychotic agents possessing pro-cognitive properties.

Lameh J, McFarland K, Ohlsson J, Ek F, Piu F, Burstein ES, Tabatabaei A, Olsson R, Bradley SR, Bonhaus DW.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Mar;385(3):313-23. doi: 10.1007/s00210-011-0702-2. Epub 2011 Nov 15.

PMID:
22083558
21.

I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors.

Carlsson ML, Burstein ES, Kloberg A, Hansson S, Schedwin A, Nilsson M, Rung JP, Carlsson A.

J Neural Transm (Vienna). 2011 Nov;118(11):1511-22. doi: 10.1007/s00702-011-0704-8. Epub 2011 Aug 28.

PMID:
21874578
22.

II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors.

Burstein ES, Carlsson ML, Owens M, Ma JN, Schiffer HH, Carlsson A, Hacksell U.

J Neural Transm (Vienna). 2011 Nov;118(11):1523-33. doi: 10.1007/s00702-011-0701-y. Epub 2011 Aug 25.

PMID:
21866391
23.

Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor.

Ma JN, Owens M, Gustafsson M, Jensen J, Tabatabaei A, Schmelzer K, Olsson R, Burstein ES.

J Pharmacol Exp Ther. 2011 Apr;337(1):275-84. doi: 10.1124/jpet.110.178194. Epub 2011 Jan 14.

PMID:
21239511
24.

Discovery of a class of calcium sensing receptor positive allosteric modulators; 1-(benzothiazol-2-yl)-1-phenylethanols.

Gustafsson M, Jensen J, Bertozzi SM, Currier EA, Ma JN, Burstein ES, Olsson R.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5918-21. doi: 10.1016/j.bmcl.2010.07.077. Epub 2010 Jul 23.

PMID:
20727747
25.

Optimization of isochromanone based urotensin II receptor agonists.

Lehmann F, Currier EA, Olsson R, Ma JN, Burstein ES, Hacksell U, Luthman K.

Bioorg Med Chem. 2010 Jul 1;18(13):4844-54. doi: 10.1016/j.bmc.2010.04.041. Epub 2010 Jun 1.

PMID:
20570157
26.

An angiotensin II type 1 receptor activation switch patch revealed through evolutionary trace analysis.

Bonde MM, Yao R, Ma JN, Madabushi S, Haunsø S, Burstein ES, Whistler JL, Sheikh SP, Lichtarge O, Hansen JL.

Biochem Pharmacol. 2010 Jul 1;80(1):86-94. doi: 10.1016/j.bcp.2010.03.006. Epub 2010 Mar 21.

27.

AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model.

Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D, Friberg M, Burstein ES, Spalding TA, Ott TR, Schiffer HH, Tabatabaei A, McFarland K, Davis RE, Bonhaus DW.

Neuropharmacology. 2010 Feb;58(2):365-73. doi: 10.1016/j.neuropharm.2009.10.003. Epub 2009 Oct 14.

PMID:
19835892
28.

Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.

Pettersson H, Bülow A, Ek F, Jensen J, Ottesen LK, Fejzic A, Ma JN, Del Tredici AL, Currier EA, Gardell LR, Tabatabaei A, Craig D, McFarland K, Ott TR, Piu F, Burstein ES, Olsson R.

J Med Chem. 2009 Apr 9;52(7):1975-82. doi: 10.1021/jm801534c.

PMID:
19338356
29.

Discovery of non-peptidergic MrgX1 and MrgX2 receptor agonists and exploration of an initial SAR using solid-phase synthesis.

Malik L, Kelly NM, Ma JN, Currier EA, Burstein ES, Olsson R.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1729-32. doi: 10.1016/j.bmcl.2009.01.085. Epub 2009 Jan 30.

PMID:
19230660
30.

Lack of evidence for AT1R/B2R heterodimerization in COS-7, HEK293, and NIH3T3 cells: how common is the AT1R/B2R heterodimer?

Hansen JL, Hansen JT, Speerschneider T, Lyngsø C, Erikstrup N, Burstein ES, Weiner DM, Walther T, Makita N, Iiri T, Merten N, Kostenis E, Sheikh SP.

J Biol Chem. 2009 Jan 16;284(3):1831-9. doi: 10.1074/jbc.M804607200. Epub 2008 Nov 18.

31.

Chemical genomics: massively parallel technologies for rapid lead identification and target validation.

Hacksell U, Nash N, Burstein ES, Piu F, Croston G, Brann MR.

Cytotechnology. 2002 Jan;38(1-3):3-10. doi: 10.1023/A:1021169023731.

32.

Identification and characterization of novel small-molecule protease-activated receptor 2 agonists.

Gardell LR, Ma JN, Seitzberg JG, Knapp AE, Schiffer HH, Tabatabaei A, Davis CN, Owens M, Clemons B, Wong KK, Lund B, Nash NR, Gao Y, Lameh J, Schmelzer K, Olsson R, Burstein ES.

J Pharmacol Exp Ther. 2008 Dec;327(3):799-808. doi: 10.1124/jpet.108.142570. Epub 2008 Sep 3.

PMID:
18768780
33.

Identification of novel selective V2 receptor non-peptide agonists.

Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F.

Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12.

PMID:
18761325
34.

Discovery of potent and selective small-molecule PAR-2 agonists.

Seitzberg JG, Knapp AE, Lund BW, Mandrup Bertozzi S, Currier EA, Ma JN, Sherbukhin V, Burstein ES, Olsson R.

J Med Chem. 2008 Sep 25;51(18):5490-3. doi: 10.1021/jm800754r. Epub 2008 Aug 23.

PMID:
18720984
35.

The human angiotensin AT(1) receptor supports G protein-independent extracellular signal-regulated kinase 1/2 activation and cellular proliferation.

Hansen JL, Aplin M, Hansen JT, Christensen GL, Bonde MM, Schneider M, Haunsø S, Schiffer HH, Burstein ES, Weiner DM, Sheikh SP.

Eur J Pharmacol. 2008 Aug 20;590(1-3):255-63. doi: 10.1016/j.ejphar.2008.05.010. Epub 2008 May 20.

PMID:
18565507
36.

Pharmacology of N-desmethylclozapine.

Lameh J, Burstein ES, Taylor E, Weiner DM, Vanover KE, Bonhaus DW.

Pharmacol Ther. 2007 Aug;115(2):223-31. Epub 2007 May 21. Review.

PMID:
17583355
37.

Identification of the atypical L-type Ca2+ channel blocker diltiazem and its metabolites as ghrelin receptor agonists.

Ma JN, Schiffer HH, Knapp AE, Wang J, Wong KK, Currier EA, Owens M, Nash NR, Gardell LR, Brann MR, Olsson R, Burstein ES.

Mol Pharmacol. 2007 Aug;72(2):380-6. Epub 2007 May 2.

PMID:
17475811
38.

In vitro pharmacology of clinically used central nervous system-active drugs as inverse H(1) receptor agonists.

Bakker RA, Nicholas MW, Smith TT, Burstein ES, Hacksell U, Timmerman H, Leurs R, Brann MR, Weiner DM.

J Pharmacol Exp Ther. 2007 Jul;322(1):172-9. Epub 2007 Apr 2.

PMID:
17403993
39.

Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation.

Spalding TA, Ma JN, Ott TR, Friberg M, Bajpai A, Bradley SR, Davis RE, Brann MR, Burstein ES.

Mol Pharmacol. 2006 Dec;70(6):1974-83. Epub 2006 Sep 7.

PMID:
16959945
40.

Integrative functional assays, chemical genomics and high throughput screening: harnessing signal transduction pathways to a common HTS readout.

Burstein ES, Piu F, Ma JN, Weissman JT, Currier EA, Nash NR, Weiner DM, Spalding TA, Schiffer HH, Del Tredici AL, Brann MR.

Curr Pharm Des. 2006;12(14):1717-29.

PMID:
16712484
41.

Constitutive activity of muscarinic acetylcholine receptors.

Spalding TA, Burstein ES.

J Recept Signal Transduct Res. 2006;26(1-2):61-85. Review.

PMID:
16595339
42.

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.

Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE.

J Pharmacol Exp Ther. 2006 May;317(2):910-8. Epub 2006 Feb 9.

PMID:
16469866
43.

Characterization of the Mas-related gene family: structural and functional conservation of human and rhesus MrgX receptors.

Burstein ES, Ott TR, Feddock M, Ma JN, Fuhs S, Wong S, Schiffer HH, Brann MR, Nash NR.

Br J Pharmacol. 2006 Jan;147(1):73-82.

44.

Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.

Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR.

J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. Epub 2005 Aug 31.

PMID:
16135699
45.

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.

Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, Hacksell U, Burstein ES, Davis RE, Brann MR.

Psychopharmacology (Berl). 2004 Dec;177(1-2):207-16. Epub 2004 Jul 16.

PMID:
15258717
46.

Pharmacology of polymorphic variants of the human 5-HT1A receptor.

Del Tredici AL, Schiffer HH, Burstein ES, Lameh J, Mohell N, Hacksell U, Brann MR, Weiner DM.

Biochem Pharmacol. 2004 Feb 1;67(3):479-90.

PMID:
15037200
47.

Discovery of novel peptide/receptor interactions: identification of PHM-27 as a potent agonist of the human calcitonin receptor.

Ma JN, Currier EA, Essex A, Feddock M, Spalding TA, Nash NR, Brann MR, Burstein ES.

Biochem Pharmacol. 2004 Apr 1;67(7):1279-84.

PMID:
15013843
48.

G-protein-coupled receptor-mediated activation of rap GTPases: characterization of a novel Galphai regulated pathway.

Weissman JT, Ma JN, Essex A, Gao Y, Burstein ES.

Oncogene. 2004 Jan 8;23(1):241-9.

PMID:
14712229
49.

Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954).

Croston GE, Olsson R, Currier EA, Burstein ES, Weiner D, Nash N, Severance D, Allenmark SG, Thunberg L, Ma JN, Mohell N, O'Dowd B, Brann MR, Hacksell U.

J Med Chem. 2002 Nov 7;45(23):4950-3.

PMID:
12408704
50.

Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H(3) receptor.

Wellendorph P, Goodman MW, Burstein ES, Nash NR, Brann MR, Weiner DM.

Neuropharmacology. 2002 Jun;42(7):929-40.

PMID:
12069903

Supplemental Content

Loading ...
Support Center